{
    "id": 1388,
    "fullName": "MET T1010I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MET T1010I (corresponds to T992I in the canonical isoform) lies within the cytoplasmic domain of the Met protein (UniProt.org). The functional effect of T1010I is conflicting, as it has been reported to have phosphorylation level and transforming capacity similar to wild-type Met protein in one study (PMID: 20670955), but in another study demonstrates increased Met transforming capability and cell migration in culture (PMID: 14559814).",
            "references": [
                {
                    "id": 332,
                    "pubMedId": 14559814,
                    "title": "c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/14559814"
                },
                {
                    "id": 2198,
                    "pubMedId": 20670955,
                    "title": "MET receptor sequence variants R970C and T992I lack transforming capacity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20670955"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "T1010I",
    "createDate": "08/12/2014",
    "updateDate": "03/13/2020",
    "referenceTranscriptCoordinates": {
        "id": 144913,
        "transcript": "NM_001127500",
        "gDna": "chr7:g.116771936C>T",
        "cDna": "c.3029C>T",
        "protein": "p.T1010I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung carcinoma cell lines harboring MET T1010I showed sensitivity to Xalkori (crizotinib) in cell culture (PMID: 17483355).",
            "molecularProfile": {
                "id": 1408,
                "profileName": "MET T1010I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 333,
                    "pubMedId": 17483355,
                    "title": "An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17483355"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19760,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in progressive disease in a patient with pre-treated non-small cell lung cancer harboring MET T1010I and KRAS G12D (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34503,
                "profileName": "KRAS G12D MET T1010I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19761,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in stable disease in a patient with pre-treated non-small cell lung cancer harboring MET T1010I and KRAS G13C (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34504,
                "profileName": "KRAS G13C MET T1010I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1408,
            "profileName": "MET T1010I",
            "profileTreatmentApproaches": [
                {
                    "id": 159,
                    "name": "MET Inhibitor",
                    "profileName": "MET T1010I"
                }
            ]
        },
        {
            "id": 34503,
            "profileName": "KRAS G12D MET T1010I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34504,
            "profileName": "KRAS G13C MET T1010I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144913,
            "transcript": "NM_001127500",
            "gDna": "chr7:g.116771936C>T",
            "cDna": "c.3029C>T",
            "protein": "p.T1010I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}